Show simple item record

dc.contributor.authorMasfarre, L.
dc.contributor.authorRocha, P.
dc.contributor.authorClave, S.
dc.contributor.authorMoliner, L.
dc.contributor.authorNavarro-Gorro, N.
dc.contributor.authorRios-Hoyo, A.
dc.contributor.authorSanchez, I.
dc.contributor.authorGiner, M.
dc.contributor.authorCorbera, A.
dc.contributor.authorTaus, A.
dc.contributor.authorBellosillo, B.
dc.contributor.authorArriola, E.
dc.date.accessioned2022-04-28T13:57:38Z
dc.date.available2022-04-28T13:57:38Z
dc.date.issued2022en
dc.identifier.citationMasfarré L, Rocha P, Clavé S, Moliner L, Navarro-Gorro N, Ríos-Hoyo A, et al. 167P KRAS G12C lung adenocarcinoma represents a distinct group of patients with different response to immunotherapy. Vol. 33, Annals of Oncology. Elsevier BV; 2022. p. S109.en
dc.identifier.doi10.1016/j.annonc.2022.02.199en
dc.identifier.urihttp://hdl.handle.net/10541/625142
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.annonc.2022.02.199en
dc.titleKRAS G12C lung adenocarcinoma represents a distinct group of patients with different response to immunotherapyen
dc.typeMeetings and Proceedingsen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]
refterms.dateFOA2022-06-28T09:40:46Z


Files in this item

Thumbnail
Name:
KRAS.pdf
Size:
94.12Kb
Format:
PDF
Description:
Identified with Open Access button

This item appears in the following Collection(s)

Show simple item record